Paricalcitol interactions
Full monograph for ParicalcitolCheck it against another medicine
Medicines
305 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Alendronic Acid + Vitamin D3 | Major | Synergy · Unknown | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive…2 documented mechanisms | 5 sources — open the full entry |
| Algae Calcium + Vitamin D3 | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Aluminium Hydroxide + Magnesium Hydroxide | Major | Absorption · Synergy | Chronic use of aluminum-containing preparations in patients with advanced renal impairment, particularly during treatment with vitamin D analogs, may result in…2 documented mechanisms | 7 sources — open the full entry |
| Aluminium Hydroxide + Magnesium Hydroxide + Simethicone | Major | Absorption · Synergy | Chronic use of aluminum-containing preparations in patients with advanced renal impairment, particularly during treatment with vitamin D analogs, may result in…2 documented mechanisms | 7 sources — open the full entry |
| Calcitriol | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Calcium + Vitamin D3 + Multimineral | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Calcium Citrate + Calcitriol | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Calcium Lactate Gluconate + Calcium Carbonate + Vitamin C + Vitamin D3 | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Calcium Lactate Gluconate + Calcium Carbonate + Vitamin D3 | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Calcium Lactate Gluconate + Calcium Carbonate + Vitamin D3 + Multiminerals | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Calcium Phosphate [Milk source] + Vitamin D3 | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Cholecalciferol [Vitamin D3] | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Conventional Calcium + Vitamin D3 | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Coral Calcium + Vitamin D3 | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Doxercalciferol | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Eggshell Calcium + Vitamin D3 | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Eggshell Calcium + Vitamin D3 + 19 Vitamin & Minerals | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Erdafitinib | Major | Others | Coadministration with agents that can alter serum phosphate levels may affect the initial dosage determination of erdafitinib. The mechanism appears to be… | 1 sources — open the full entry |
| Ibandronic Acid + Algae Calcium + Vitamin D3 | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Ibandronic Acid + Coral Calcium + Vitamin D3 | Major | Synergy | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive… | 5 sources — open the full entry |
| Sucralfate | Major | Absorption | Chronic use of aluminum-containing preparations in patients with advanced renal impairment, particularly during treatment with vitamin D analogs, may result in… | 3 sources — open the full entry |
| Vitamin C + Vitamin D3 + Folic acid | Major | Synergy · Unknown | Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive…2 documented mechanisms | 5 sources — open the full entry |
| Abametapir | Moderate | Metabolism | Based on in vitro inhibition data, a single topical application of abametapir lotion may increase plasma concentrations of drugs that are substrates of CYP450… | 1 sources — open the full entry |
| Aluminium Oxide + Magnesium Trisilicate | Moderate | Synergy | Use of magnesium-containing products with a vitamin D analog may increase the risk of hypermagnesemia, particularly in chronic renal dialysis patients, due to… | 4 sources — open the full entry |
| Apalutamide | Moderate | Absorption · Metabolism | Coadministration with apalutamide may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4, 2C9, 2C19, breast… | 5 sources — open the full entry |
| Asciminib | Moderate | Metabolism | Coadministration with asciminib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is… | 1 sources — open the full entry |
| Atenolol + Chlorthalidone | Moderate | Synergy · Unknown | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients…2 documented mechanisms | 15 sources — open the full entry |
| Azilsartan Medoxomil + Chlorthalidone | Moderate | Synergy | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients… | 15 sources — open the full entry |
| Bisoprolol Fumarate + Hydrochlorothiazide | Moderate | Synergy · Unknown | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients…2 documented mechanisms | 15 sources — open the full entry |
| Calcium acetate + Magnesium carbonate | Moderate | Synergy | Use of magnesium-containing products with a vitamin D analog may increase the risk of hypermagnesemia, particularly in chronic renal dialysis patients, due to… | 4 sources — open the full entry |
| Candesartan Cilexetil + Hydrochlorothiazide | Moderate | Synergy | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients… | 15 sources — open the full entry |
| Carbamazepine | Moderate | Metabolism | Coadministration with CYP450 inducers such as rifampin, isoniazid, barbiturates, and certain anticonvulsants may decrease the pharmacologic effects of vitamin… | 4 sources — open the full entry |
| Ceritinib | Moderate | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of paricalcitol, which is partially metabolized by… | 4 sources — open the full entry |
| Chlorthalidone | Moderate | Synergy | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients… | 15 sources — open the full entry |
| Clarithromycin | Moderate | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of paricalcitol, which is partially metabolized by… | 4 sources — open the full entry |
| Digoxin | Moderate | Synergy | Excessive dosing of vitamin D can induce hypercalcemia, which may increase the risk of digitalis toxicity and serious arrhythmias due to additive inotropic… | 6 sources — open the full entry |
| Enzalutamide | Moderate | Metabolism | Coadministration with enzalutamide may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4, 2C9, 2C19, and/or P-glycoprotein (P-gp)… | 4 sources — open the full entry |
| ErythromycinLotionOral | Moderate | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of paricalcitol, which is partially metabolized by… | 4 sources — open the full entry |
| Esomeprazole + Amoxicillin + Clarithromycin | Moderate | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of paricalcitol, which is partially metabolized by… | 4 sources — open the full entry |
| Fosphenytoin Sodium | Moderate | Metabolism | Coadministration with CYP450 inducers such as rifampin, isoniazid, barbiturates, and certain anticonvulsants may decrease the pharmacologic effects of vitamin… | 4 sources — open the full entry |
| Hydrochlorothiazide | Moderate | Synergy | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients… | 15 sources — open the full entry |
| Indapamide | Moderate | Synergy | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients… | 15 sources — open the full entry |
| Indapamide + Amlodipine | Moderate | Synergy · Unknown | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients…2 documented mechanisms | 15 sources — open the full entry |
| Irbesartan + Hydrochlorothiazide | Moderate | Synergy · Unknown | Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients…2 documented mechanisms | 15 sources — open the full entry |
| Iron Sucrose | Moderate | Absorption | Coadministration with sucroferric oxyhydroxide may reduce the oral bioavailability of vitamin D analogs. The proposed mechanism involves nonspecific adsorption… | 1 sources — open the full entry |
| Itraconazole | Moderate | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of paricalcitol, which is partially metabolized by… | 4 sources — open the full entry |
| Ketoconazole | Moderate | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of paricalcitol, which is partially metabolized by… | 4 sources — open the full entry |
| Ketoconazole + Zinc Pyrithione + Aleovera | Moderate | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of paricalcitol, which is partially metabolized by… | 4 sources — open the full entry |
| Lamivudine + Zidovudine + Nevirapine | Moderate | Metabolism | Coadministration with nevirapine may decrease the plasma concentrations and therapeutic efficacy of drugs that are substrates of CYP450 3A4. The proposed… | 4 sources — open the full entry |
| Lansoprazole + Amoxicillin + Clarithromycin | Moderate | Metabolism · Unknown | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of paricalcitol, which is partially metabolized by…2 documented mechanisms | 4 sources — open the full entry |
Conditions
Conditions in which Paricalcitol needs care, as documented in this source.
Arrhythmias, Cardiac
MajorParicalcitol, a vitamin D analog, reduces hyperparathyroidism associated with chronic renal failure without significant increase in serum calcium levels. Serum calcium and phosphate concentrations can increase during therapy with paricalcitol and may exacerbate arrhythmias, particularly in patients receiving cardiac glycosides. Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias. Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended. .
1 source
- "Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical (2001):
Hypercalcemia
MajorVitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.
4 sources
- "Product Information. Rocaltrol (calcitriol)." Roche Laboratories (2001):
- "Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical (2001):
- "Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc (2002):
- "Product Information. Drisdol (ergocalciferol)." sanofi-aventis (2016):
Water-Electrolyte Imbalance
MajorVitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or renal systems or other soft tissue calcifications. A solubility product (Serum Calcium X Phosphate) should not exceed 70. Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.
4 sources
- "Product Information. Calciferol (ergocalciferol)." Schwarz Pharma (2001):
- "Product Information. Rocaltrol (calcitriol)." Roche Laboratories (2001):
- "Product Information. Calderol (calcifediol)." Organon (2001):
- "Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical (2001):
Liver Diseases
ModerateParicalcitol is metabolized by the liver. Parent compound and metabolites are primarily eliminated by in the bile and feces. Paricalcitol metabolites have not been characterized or identified. Metabolic and therapeutic activity of paricalcitol may be altered in patients with hepatic impairment. Therapy with paricalcitol should be administered cautiously in patients with hepatobiliary dysfunction. Clinical monitoring of hepatobiliary function, parathyroid hormone and calcium levels is recommended.
1 source
- "Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical (2001):
Therapeutic duplication
Drug classes that overlap with Paricalcitol, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.
vitamin d analogs
The recommended maximum number of medicines in the 'vitamin d analogs' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'vitamin d analogs' category.
Example product in the source data (US market): Os-cal extra d3
vitamin d analogs
The recommended maximum number of medicines in the 'vitamin d analogs' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'vitamin d analogs' category.
Example product in the source data (US market): Ortho df
vitamin d analogs
The recommended maximum number of medicines in the 'vitamin d analogs' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'vitamin d analogs' category.
Example product in the source data (US market): Alendronate/cholecalciferol